Cannabis Law Report

NOVEMBER 16, 2021

For multiple health and safety reasons, we believe orally dosed MYMD-1 is vastly superior to any of the available TNF inhibitors on the market today, one of which is the best-selling drug in the world.”. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 26, 2021

MyMD’s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JULY 9, 2021

Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level.

Law 105

Law Therapy Clinical Trials Research and Development 105

The Cannigma

DECEMBER 12, 2022

Now, psychedelic research is booming. And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. 19 20 21 22 23.

History 119

History Microdosing Research and Development Clinical Trials 119

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

NOVEMBER 10, 2021

– Multiple Contracts Awarded to Support the Development and Manufacturing of Envelta (NES100) – BERWYN, Pa.–(BUSINESS as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies. –(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

OCTOBER 22, 2021

The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. BX-1: Bionorica SE BX-1 is an oral solution containing dronabinol, being developed by Bionorica.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

Cannabis Law Report

OCTOBER 18, 2021

The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. BX-1 is an oral solution containing dronabinol, being developed by Bionorica. BX-1: Bionorica SE. VSN16R: Canbex Therapeutics.

Research and Development 52

Research and Development Pharmaceutical Chronic Pain Therapy 52

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). major depressive disorder, post-traumatic stress disorder, acute suicidality).

Therapy 90

Therapy Legalization Chronic Pain DEA 90

Cannabis Law Report

DECEMBER 28, 2021

These accomplishments include accelerated development of our existing product candidates, broadening our pipeline of product candidates, and utilizing grants where appropriate. We recently announced that we anticipate commencing our initial human trial for Epoladerm™ in the second quarter of 2022.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Alchimia

FEBRUARY 1, 2022

To date, there are several studies that have tried to verify the safety and toxicology of CBD when it is administered to treat certain diseases. Some of the participants in such studies, such as the one conducted to determine the safety and effectiveness of CBD in treating epilepsy , reported the following side effects: Diarrhea.

CBD 52

CBD Epilepsy Research and Development Cannabinoids 52

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). major depressive disorder, post-traumatic stress disorder, acute suicidality).

Legalization 52

Legalization Therapy Chronic Pain DEA 52

Cannabis Law Report

NOVEMBER 24, 2021

Published by The Journal of Cannabis Research. However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive.

Research and Development 52

Research and Development Medicine Access Media 52

The Cannigma

MARCH 12, 2021

We’re not going to get over the fact that there’s not the same sort of clinical trial and that type of evidence for cannabis and cannabis treatments in the very near future for various reasons. And in my belief, it should be cannabis, because of the safety profile, number one. RF: That’s absolutely the case.

Legalization 128

Legalization Patients Education Dispensary 128

Cannabis Law Report

MAY 13, 2019

Researchers from the Queensland University of Technology conducted a wide-ranging review of 26 published studies across Australia, the United States, Canada and Ireland. For instance, it has been very challenging to perform clinical trials on herbal cannabis due to the enduring illicit status of cannabis across much of the world.

Medicine 45

Medicine Research and Development Clinical Trials Data 45

Cannabis Law Report

AUGUST 30, 2019

The National Institute on Drug Abuse published a grant notice to encourage research on the effects of changing US cannabis laws and policies on public health. Iowa’s Medical Cannabidiol Board formally approved a measure to add chronic pain to the list of conditions that qualify a patient for medical cannabis.

Banking 45

Banking Research and Development Legislation Programs 45

Cannabis Law Report

OCTOBER 17, 2019

Food and beverage makers are gearing up to sell CBD-containing products, when allowed by regulators, including Lagunitas Brewing, which has developed a cannabis-infused IPA and a THC-based sparkling water, and Ben & Jerry’s, which plans to offer a CBD-infused ice cream. billion in 2025, according to Grandview Research.

Law 40

Law Seed-To-Sale Hemp Recreational 40